TransMedics Group, Inc. (NASDAQ:TMDX) CEO Sells $1,141,080.00 in Stock

TransMedics Group, Inc. (NASDAQ:TMDX) CEO Waleed H. Hassanein sold 12,000 shares of TransMedics Group stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $95.09, for a total value of $1,141,080.00. Following the transaction, the chief executive officer now owns 74,087 shares in the company, valued at approximately $7,044,932.83. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

TransMedics Group Trading Down 2.3 %

Shares of TMDX traded down $2.13 during midday trading on Friday, hitting $91.82. 679,800 shares of the stock were exchanged, compared to its average volume of 681,876. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $99.63. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The stock has a fifty day simple moving average of $82.70 and a 200 day simple moving average of $71.76. The firm has a market cap of $3.00 billion, a P/E ratio of -119.25 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, February 26th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.22. The company had revenue of $81.20 million during the quarter, compared to analysts’ expectations of $68.49 million. TransMedics Group had a negative return on equity of 2.35% and a negative net margin of 10.36%. TransMedics Group’s revenue for the quarter was up 158.6% on a year-over-year basis. During the same period last year, the business posted ($0.21) EPS. On average, research analysts anticipate that TransMedics Group, Inc. will post -0.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in TransMedics Group by 1.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company’s stock worth $99,341,000 after purchasing an additional 29,798 shares during the period. Moody Aldrich Partners LLC boosted its stake in shares of TransMedics Group by 110.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 46,312 shares of the company’s stock valued at $3,655,000 after buying an additional 24,290 shares during the period. American Century Companies Inc. grew its position in shares of TransMedics Group by 271.2% during the third quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock worth $26,661,000 after buying an additional 355,755 shares in the last quarter. Eagle Health Investments LP increased its stake in shares of TransMedics Group by 78.5% during the third quarter. Eagle Health Investments LP now owns 414,205 shares of the company’s stock worth $22,678,000 after buying an additional 182,173 shares during the period. Finally, Qube Research & Technologies Ltd raised its holdings in TransMedics Group by 31.2% in the third quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company’s stock valued at $4,624,000 after acquiring an additional 20,081 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Morgan Stanley lifted their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. Oppenheimer lifted their target price on TransMedics Group from $92.00 to $105.00 and gave the company an “outperform” rating in a research report on Tuesday, February 27th. JPMorgan Chase & Co. upped their price target on TransMedics Group from $87.00 to $105.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Finally, Piper Sandler began coverage on TransMedics Group in a research report on Thursday, March 28th. They set an “overweight” rating and a $95.00 price objective for the company. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and an average target price of $102.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.